Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




May
02
Today In Oncology
FDA Approves Vepdegestrant for ER-HER2 ESR1 Advanced Breast Cancer
Melanoma Gut Microbiome May Help Predict Recurrence After Immunotherapy
Association of Body Size and Bladder Cancer Risk
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Can PFAS Exposure Raise ALL Risk?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo